Coenzyme Q10 (ubidecarenone) is a cofactor for mitochondrial energy production and an antioxidant; in the Q-SYMBIO trial of 420 patients with moderate to severe heart failure, two years of oral coenzyme Q10 reduced major adverse cardiovascular events (15% against 26% on placebo).
established — replicated in humans, or settled by a regulator
every claim resolves to its source
All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
Summary
Coenzyme Q10 (ubidecarenone) is a cofactor for mitochondrial energy production and an antioxidant; in the Q-SYMBIO trial of 420 patients with moderate to severe heart failure, two years of oral coenzyme Q10 reduced major adverse cardiovascular events (15% against 26% on placebo). · pmid:25282031
A meta-analysis of six randomized trials in 302 statin-treated patients found no significant effect of coenzyme Q10 on muscle pain or creatine kinase. · pmid:25440725
Proportion of the 2 claims about Ubidecarenone (injectable CoQ10) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Ubidecarenone (injectable CoQ10) yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
Approved-label dose· a resolved regulatory document names a labelled dose
nothing resolved on this rung
Studied human doses· resolved human studies at the established tier
Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. · pmid 25440725 · 2015
Observational evidence· resolved human data at the emerging tier: thin, or contested
The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. · pmid 25282031 · 2014
Community-reported protocols· protocol propositions from distinct members, counted once per human
nothing resolved on this rung
Preclinical evidence· resolved animal, cell or mechanistic work
nothing resolved on this rung
2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.